The Taizhou Medical High-tech Zone, located in Taizhou city, East China's Jiangsu province, added five municipal key laboratories earlier this year, injecting strong momentum into the area's health sector.
One of them that has become a benchmark is the Key Laboratory of Preparation and Evaluation of Intravenous Emulsion in Taizhou, operated by Jiangsu Yingke Biopharmaceutical.
Another is the Key Laboratory of Target Discovery and Validation of New Drugs, established by the Medical Innovation Center (Taizhou) of Peking University.
An artist's impression of the premises of Jiangsu Yingke Biopharmaceutical. [Photo/WeChat account: weigg6666]
The Key Laboratory of Preparation and Evaluation of Intravenous Emulsion in Taizhou focuses on tackling core technologies such as drug loaded emulsions and parenteral nutrition emulsions, with the task of introducing a series of differentiated product systems.
There are currently 16 ongoing projects being conducted by the Key Laboratory of Target Discovery and Validation of New Drugs in Taizhou, with research on ganoderic acid A being impressive, according Yang Baoxue, director of the lab.
The researchers there have been conducting experimental work on the pharmacological effects, dose-responses and safety evaluations of ganoderic acid A in the prevention and treatment of non-alcoholic fatty liver disease.
In recent years, the Taizhou zone has leveraged the favorable provincial and municipal support for the health industry, actively encouraging business enterprises to apply for municipal key laboratories. As a result, there is currently one national key laboratory, as well as 19 municipal key laboratories in the district.